Latest Biotechnology, Pharmaceutical and Healthcare News from Cancer Networks

09:49 EDT 19th August 2018 | BioPortfolio

Here are the most relevant search results for "Cancer Networks" found in our extensive news archives from over 250 global news sources.

More Information about Cancer Networks on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cancer Networks for you to read. Along with our medical data and news we also list Cancer Networks Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cancer Networks Companies for you to search.

Showing News Articles 1–25 of 385 from Cancer Networks

Thursday 28th June 2018

Will DNA Vaccine TetMYB Be a Game-Changer in Advanced Colorectal Cancer?

Thu, 28 Jun 2018:06An Australian team is studying a DNA-based vaccine that the lead investigator feels could be “transformative” in the care of advanced colorectal cancer.

Wednesday 27th June 2018

OS Boost With Quizartinib in R/R AML

Wed, 27 Jun 2018:06This study is the first to show significantly improved OS from single-agent treatment in this particularly difficult to treat population.

Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma

Wed, 27 Jun 2018:06The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma.

Tuesday 26th June 2018

Role for PET Imaging in Reducing Tx Toxicity in Advanced Hodgkin Lymphoma?

Wed, 27 Jun 2018:06De-escalated treatment may be possible in patients with advanced HL who reach a metabolic response after only 2 cycles of escalated BEACOPP.

Nivolumab Is China’s First Approved Immuno-Oncology Drug

Wed, 27 Jun 2018:06In CheckMate -078, nivolumab yielded superior OS compared with docetaxel in previously treated NSCLC, regardless of PD-L1 expression and tumor histology.

CDK12 Loss a Biomarker for Prostate Cancer Response to Immunotherapy?

Thu, 28 Jun 2018:06DNA and RNA sequencing results suggest prostate cancer treatment “involving inhibition of CDK12 and immune checkpoint blockade,” a U Michigan team said.

MM Patients May Benefit From Surgery, Regardless of Lesion Location

Wed, 27 Jun 2018:06Preoperative pain, prothrombin time activity (PTA), albumin, urine protein, and postoperative chemotherapy appeared to be associated with prognosis.

Meta-Analysis: Long Delays in the Diagnostic Pathway to MM

Wed, 27 Jun 2018:06Many MM patients experience a diagnostic interval longer than 3 months until diagnosis is confirmed, and several factors may account for this.

Pooled Data Analysis: Vitamin D Protects Against Colorectal Cancer

Tue, 26 Jun 2018:06For each 25 nmol/L increment of circulating vitamin D, colorectal cancer risk was 19% lower in women and 7% lower in men.

Culprit in Regorafenib Combo Failure in Metastatic Colorectal Cancer?

Tue, 26 Jun 2018:06A 13% absolute increase in the radiographic response rate occurred in regorafenib-treated patients. Survival increases were not statistically significant.

Monday 25th June 2018

TRBV Gene Use Could Act as Biomarker in HER2+ Breast Cancer

Tue, 26 Jun 2018:06Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.

Prolonged PFS With Obinutuzumab in Advanced FL, Regardless of Chemo Backbone

Mon, 25 Jun 2018:06AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms.

Ibrutinib Monotherapy Not Recommended for R/R FL

Mon, 25 Jun 2018:06In the DAWN trial, however, investigators said, “some patients experienced prolonged remission durations and symptom relief with no new safety signals.”

Fewer Genetic Testing Referrals for Minorities With Ovarian Cancer

Mon, 25 Jun 2018:06Following diagnosis, only one-third of black women in this retrospective study were referred to genetic counselors—and none actually received counseling.

BMI Inversely Associated With Risk of Premenopausal Breast Cancer

Mon, 25 Jun 2018:06The inverse association with premenopausal breast cancer was seen across the entire distribution of BMI, and at a higher magnitude than previously reported.

Lenalidomide/Rituximab Combo Effective in Advanced FL

Mon, 25 Jun 2018:06Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile.

Friday 22nd June 2018

Metabolomic Analysis May Provide Non-Invasive Bladder Cancer Surveillance

Fri, 22 Jun 2018:06A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.

Thursday 21st June 2018

Higher Indel Counts Linked to Improved OS in RCC

Thu, 21 Jun 2018:06In RCC patients on anti–PD-1 therapy, besides the indel count link to better OS, baseline tumor infiltration with M2 macrophages predicted improved PFS.

Study IDs Common RCC Subtype in Peds, Young Adults

Thu, 21 Jun 2018:06This is the first diagnostic classification of RCCs in patients younger than age 30 prospectively registered in a cooperative group clinical study.

Liquid Biopsy to Inform Targeted Tx of Colorectal Cancer

Thu, 21 Jun 2018:06In this video, Dr. Heinz-Josef Lenz outlines the many advantages that development of liquid biopsy is affording cancer patients.

Thursday 7th June 2018

Secondary Surgery Fails to Improve Outcomes in Recurrent Ovarian Cancer

Dave LevitanJun 7, 2018Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.

Weekly Online Symptoms Survey Linked to Prolonged OS in Lung Cancer

Bryant FurlowJun 7, 2018Weekly patient symptom self-reports, filed using an online tool, allowed timely detection of lung cancer relapses and prolonged patient survival.

Wednesday 6th June 2018

T-VEC Immunotherapy Shows Promising Early Activity in Melanoma

Bryant FurlowJun 7, 2018The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB–IVM1a melanoma.

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC

John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab–based therapy.

AR-V7+ CTCs Predicted Worse PFS, OS in mCRPC

Leah LawrenceJun 6, 2018In the PROPHECY study, men with mCRPC and AR-V7–positive CTCs had only a 0% to 11% probability of benefit from abiraterone or enzalutamide.

Quick Search


News Quicklinks